NO20064239L - Anti-AB-antistoff - Google Patents

Anti-AB-antistoff

Info

Publication number
NO20064239L
NO20064239L NO20064239A NO20064239A NO20064239L NO 20064239 L NO20064239 L NO 20064239L NO 20064239 A NO20064239 A NO 20064239A NO 20064239 A NO20064239 A NO 20064239A NO 20064239 L NO20064239 L NO 20064239L
Authority
NO
Norway
Prior art keywords
abeta
antibody
free
low levels
abeta peptide
Prior art date
Application number
NO20064239A
Other languages
English (en)
Inventor
Don B Mcclure
Ronald Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20064239L publication Critical patent/NO20064239L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse frembringer en sammensetning som er egnet for administrering til et menneske omfattende et anti- A(-antistoff som er fritt for A(-peptid eller som har akseptable lave nivåer av dette, fritt for ikke-humant A(-peptid eller som har akseptable lave nivåer av dette, eller som har en upåvisbar konsentrasjon av A(-peptid.
NO20064239A 2004-02-23 2006-09-19 Anti-AB-antistoff NO20064239L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (1)

Publication Number Publication Date
NO20064239L true NO20064239L (no) 2006-11-20

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064239A NO20064239L (no) 2004-02-23 2006-09-19 Anti-AB-antistoff

Country Status (20)

Country Link
US (1) US20070190046A1 (no)
EP (1) EP1720909B1 (no)
JP (1) JP4851348B2 (no)
KR (2) KR100889430B1 (no)
CN (1) CN1922209B (no)
AT (1) ATE534667T1 (no)
AU (1) AU2005217596B2 (no)
BR (1) BRPI0507856A (no)
CA (1) CA2556436C (no)
CY (1) CY1112162T1 (no)
DK (1) DK1720909T3 (no)
EA (1) EA009872B1 (no)
ES (1) ES2375627T3 (no)
IL (1) IL177611A (no)
NO (1) NO20064239L (no)
PL (1) PL1720909T3 (no)
PT (1) PT1720909E (no)
SI (1) SI1720909T1 (no)
UA (1) UA93181C2 (no)
WO (1) WO2005082939A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
BRPI0619748B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL2104682T3 (pl) 2007-01-11 2017-03-31 Michael Bacher Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
WO2018031334A1 (en) * 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2022150735A1 (en) 2021-01-11 2022-07-14 Eli Lilly And Company Anti-n3pglu amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129820A0 (en) 1996-12-23 2000-02-29 Elan Pharm Inc Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
CN101670105B (zh) * 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7318923B2 (en) * 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies

Also Published As

Publication number Publication date
CA2556436C (en) 2014-04-01
PT1720909E (pt) 2011-12-23
AU2005217596B2 (en) 2012-01-19
CY1112162T1 (el) 2015-12-09
CN1922209A (zh) 2007-02-28
KR20060126785A (ko) 2006-12-08
JP2008500279A (ja) 2008-01-10
CN1922209B (zh) 2012-09-05
DK1720909T3 (da) 2012-01-30
US20070190046A1 (en) 2007-08-16
WO2005082939A2 (en) 2005-09-09
EA009872B1 (ru) 2008-04-28
KR100889430B1 (ko) 2009-03-23
SI1720909T1 (sl) 2012-01-31
IL177611A (en) 2013-05-30
WO2005082939A3 (en) 2005-10-27
CA2556436A1 (en) 2005-09-09
EP1720909B1 (en) 2011-11-23
BRPI0507856A (pt) 2007-07-10
AU2005217596A1 (en) 2005-09-09
UA93181C2 (ru) 2011-01-25
PL1720909T3 (pl) 2012-04-30
ATE534667T1 (de) 2011-12-15
EA200601545A1 (ru) 2007-02-27
ES2375627T3 (es) 2012-03-02
KR20090005410A (ko) 2009-01-13
IL177611A0 (en) 2006-12-10
EP1720909A2 (en) 2006-11-15
JP4851348B2 (ja) 2012-01-11

Similar Documents

Publication Publication Date Title
CY1112162T1 (el) Αντι-αβ αντισωμα
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
CO5720212A1 (es) Composicion de anticuerpo her2
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CU24058B1 (es) Antagonistas de pcsk9
EA200700702A1 (ru) Аналоги локсапина и способы их применения
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200800812A1 (ru) Композиции антитела против cd3
MY174493A (en) Binding agents
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MEP35408A (en) Tweak binding antibodies
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
DE602005012097D1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
EA200800601A1 (ru) Связывающие fas антитела
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
RU2010100549A (ru) Способ получения n-(1,3,5-дитиазинан-5-ил)-изоникотинамида и n-(2,4,6-триметил-1,3,5-дитиазинан-5-ил)-изоникотинамида
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
EA200970159A1 (ru) Композиция, содержащая полифенол и пептид, и ее применение для поддержания здоровья желудка
UY28629A1 (es) Procedimiento para preparar triamidas de ácido trimesínico dendríticas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application